Introduction
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Frequency and Sensitivity of Extended Spectrum Beta-Lactamase Positive Organisms in a Secondary and Tertiary Level Hospital Network in Dhaka
USA in late 1988. 4, 5 In Bangladesh, it was reported first in 2001. 6 ESBLs are enzymes that mediate resistance to β-lactam antibiotics, viz., penicillins, cephalosporins and monobactams, but do not affect cephamycins or carbapenems. Because of greatly extended substrate range, these enzymes are called extended spectrum β-lactamases. 2 ESBL enzymes are most commonly produced by Escherichia coli (E. coli) and Klebsiella spp. and to some extent by other members of Enterobacteriaceae and Pseudomonadaceae. 2, 7 ESBL organisms have continued to increase in varieties (more than 400 variants detected) 8 and prevalence and are now a global health concern. 4, 9, 10 The ESBL organisms have implications for clinicians and patients because these are associated with treatment failure, increased morbidity and mortality, poor outcomes, increased length of stay (LOS) in hospital and health care costs. 9 So, it is important to treat it properly as soon as it is diagnosed. Aim of this study was to observe the current status of antibiogram of ESBL positive organisms and their prevalence in and around Dhaka city.
Materials and Methods
This cross-sectional study was done in the Department of Microbiology, Bangladesh Institute of Health Sciences (BIHS) General Hospital, Dhaka, Bangladesh from March, 2012 to February, 2013. Specimens were collected from inpatient and outpateint departments of BIHS General Hospital and nine more hospitals/centres of Dhaka city affiliated to BIHS General Hospital.
Organisms isolated from urine and pus of 472 subjects were studied. There were 411 urine and 61 pus specimens. Pus was collected from diabetic foot lesions, post surgical infected wounds and traumatic wounds. Only E. coli and Klebsiella spp. were included in this study. Isolation, identification and antibiotic sensitivity of the organisms were done by standard procedures.
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For detection of ESBL positive organisms, screening test 15 was done along with routine sensitivity test. Positive screening tests were confirmed later by Phenotypic Confirmatory Test (PCT).
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Screening test
Disks of cefotaxime (CTX), ceftazidime (CAZ) and amoxycillin/clavulanic acid (AMC) were placed in a line, placing AMC in the centre and other two on either side about 30 mm apart from centre to centre. Widening of cephalosporin's inhibition zone adjacent to the disk containing AMC was regarded as ESBL positive.
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Phenotypic confirmtory test (PCT)
In this method, two sets were used. One set consisted of ceftazidime (30 µg) disk and ceftazidime/clavulanic acid (30/10 µg) disk. Another set consisted of cefotaxime (30 µg) disk and cefotaxime/clavulanic acid (30/10 µg). The disks among the sets were placed at least 30 mm apart (centre to centre). When the zone of inhibition by combination disks (ceftazidime/clavulanic acid or cefotaxime/clavulanic acid) was >5 mm than the zone of inhibition produced by ceftazidime/cefotaxime alone, the test was taken as PCT positive.
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Media for sensitivity
Muller Hinton agar (Oxoid) 13, 14 Antibiotic disks used All the isolates were tested for sensitivity to amoxycillin/clavulanic acid (20/10 µg), cefotaxime (30 µg), ceftazidime (30 µg), cefradine (30 µg), cefoxitin (30 µg), ampicillin (10 µg), amikacin (30 µg), imipenem (10 µg), gentamicin (10 µg), ciprofloxacin (5 µg), nalidixic acid (30 µg), nitrofurantoin (300 µg), doxycycline (30 µg), cotrimoxazole (1.25/23.75 µg), colistin (10 µg), tigecycline (15 µg) and piperacillin/ tazobactam (100 µg/10 µg). 13 The above mentioned antibiotic discs were placed on Muller Hinton agar according to standard procedure.
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Results
Isolation of ESBL positive organisms in BIHS General
Hospital and different hospitals/centres located at different sites of Dhaka city has been shown in 20 However, prevalence of ESBL positive organisms is increasing throughout the world. 4 Predominating organism in our study was E. coli (82.8%, n=472) and the rest (17.2%) was Klebsiella spp.; 54.5% of E. coli (n=391) and 44.4% of Klebsiella spp. (n=81) were ESBL positive. These findings are consistent with the study of Rahman et al 6 and Sashirekha. 16 In the study of Rahman et al 6 predominating organism was E. coli (54.4%, n=241) of which 43.2% were ESBL positive and 45.6% were K. pneumoniae of which 39.5% were ESBL positive.
In the study of Sashirekha 17 were lower.
ESBL producing organism is now a global threat 1 and its treatment has become difficult because of drug resistance over a wide spectrum of β-lactam and non β-lactam drugs. In this study, in case of most antibiotics the difference of sensitivity between ESBL positive and ESBL negative organisms was statistically significant.
All ESBL positive organisms (100%) were found resistant to cephalosporins (except cephamycins as discussed below) and monobactams while all (100%) ESBL negative organisms were sensitive to these drugs. Other authors showed varying degrees of sensitivity of ESBL producers to cephalosporins. 1, 16, 17 It is to be noted that ESBL producers should be taken as resistant to all cephalosporins and monobactams even if these show sensitivity against some of the members. Cefepime is considered as a therapeutic option by some authors, but clinical data show high failure rate. 20 Some patients with ESBL positive organisms were treated successfully with cephalosporins where organisms appeared sensitive in disc diffusion methods and had very low MIC. 1, 16, 17, 21, 22 However, MIC is not done routinely in our department except in cases of multidrug resistance when higher than MIC level of antibiotic is targeted.
Currently, carbapenems are the most effective antibiotic for treatment of infections due to ESBL producing organisms as the outcome is better than treatment with other antibiotics. 4, 18, 22, 23 This has been true in this study also where all (100%, n=391) E coli strains, both ESBL positive and negative, were sensitive to imipenem. This is consistent with the findings of Sasirekha (n=225) 16 , Yasmin (n=201) 19 and Paterson 23 who also found 100% of isolates sensitive to imipenem. Dalela (n=215) 17 found 98.5% (n=135) of ESBL producer and 94% (n=219) of non-ESBL producers sensitive to imipenem and Ahmed et al 1 found 98.3% of ESBL producer E. coli sensitive to imipenem. However, 5.6% of ESBL positive Klebsiella spp. in our study showed resistance to imipenem which is similar to the study of Hawser et al 24 where 10% of ESBL positive Klebsiella spp. were resistant to imipenem; but it contrasts with the study of Sasirekha 16 , Yasmin 19 and Paterson 23 who found all ESBL producing Klebsiella spp. sensitive to imipenem. Imipenem resistance of ESBL positive Klebsiella spp. is increasing all over the world day by day. 22 In this study all isolates except ESBL positive Klebsiella spp. were found sensitive to tigecycline; 80.6% of ESBL +ve Klebsiella spp. were sensitive to tigecycline. In other studies, it was found that tigecycline had excellent in vitro sensitivity but data reflecting clinical outcome is lacking. 20, 23, 25 It was also reported that there was increased mortality rate in tigecycline-treated patients than in patients treated by other antibiotics. 20 FDA warned health professionals and their medical care organizations about the increased risk of death when intravenous tigecycline is used. They suggested to reserve tigecycline for use only in situations when alternative treatments are not suitable. 26 About 94% of ESBL positive E. coli were found sensitive to colistin in this study. All ESBL negative E. coli and all Klebsiella spp. were sensitive to colistin. Other studies also demonstrated its efficacy in treating multidrug resistant organisms including ESBL producers. 20, 23 Although recent studies have shown that it has acceptable effectiveness and has been used to treat infections due to multiresistant Gram-negative organisms, its use should be reserved as a last resort mainly for ESBL producing bacteria that are also resistant to aminoglycosides and carbapenems. 25 In this study, <20% ESBL producers and >80% non-ESBL producers (both E. coli and Klebsiella) were sensitive to amoxycillin/clavulanic acid. In the study of Dalela 17 , 15.6% of ESBL producers and 23.8% of non-ESBL producers were sensitive to amoxycillin/ clavulanic acid.
In our study all (100%) ESBL negative E. coli and Klebsiella spp. were found sensitive to piperacillin/tazobactam whereas 90.6% of ESBL positive E. coli and 80.6% of ESBL positive Klebsiella spp. were sensitive to piperacillin/tazobactam. Dalela 17 found 65.5% of non-ESBL producers and 72.6% of ESBL producers sensitive to piperacillin/tazobactam. Sasirekha 16 found about 70% of non-ESBL producers and 60% of ESBL producers sensitive to piperacillin/tazobactam. Other studies showed that clinical experience with β-lactam/β-lactamase inhibitor combinations in the treatment of severe infections due to ESBL producers is limited and showed mixed results; but it may be an option of treatment for infections like urinary tract infections (UTI) caused by susceptible ESBLs. [20] [21] [22] [23] The cephamycins (e.g. cefoxitin) which are also 2 nd generation cephalosporins demonstrate markedly greater resistance to microbial degradation by β-lactamases than is normally displayed by the cephalosporins. 22 In our study, 85.9% of ESBL positive and 100% of ESBL negative E. coli and 86.1% of ESBL positive and 93.3% of ESBL negative Klebsiella were sensitive to cefoxitin. However, clinical data regarding its use is scarce and clinical failure has been documented due to co-resistance. 4, 20 In this study about 76.5% of ESBL positive and 77% ESBL negative strains of E. coli showed sensitivity against amikacin and comparatively it was higher in ESBL positive (83.3%) and ESBL negative (88.9%) Klebsiella spp. These findings are consistent with that of Yasmin 19 who found 83% of E. coli and 81% of Klebsiella spp. sensitive to amikacin. Dalela 17 found 64.5% of ESBL producers and 46.4% of non-ESBL producer organisms sensitive to amikacin. About 78% ESBL producers and 60% of non-ESBL producers were susceptible to amikacin in the study of Ahmed et al. 1 But in contrast to these findings less sensitivity was observed in the study of Sasirekha 16 where only 30% of ESBL producers and about 40% of non-ESBL producers were sensitive to amikacin.
In our study, 77.5% of ESBL positive E. coli and 55.6% of ESBL positive Klebsiella spp. were sensitive to gentamicin whereas 94.4% of ESBL negative E. coli and 97.8% of ESBL negative Klebsiella spp. were sensitive to this drug. In the study of Ahmed et al 1 34.8% of ESBL positive and 21.5% of ESBL negative E. coli were sensitive to gentamicin. However, aminoglycosides may be potentially useful in the treatment of complicated urinary tract infections due to ESBL-producing organisms; but these are not recommended as routine monotherapy for severe infections at other sites. 20, 23 Nitrofurantoin was used in case of urine isolates only; both ESBL positive and ESBL negative E. coli were found almost equally sensitive (~85%). But Klebsiella spp. showed different figure -31 While reporting the culture and sensitivity tests, the ESBL positive organisms should be pointed out with comment like this -"The organisms are ESBL positive and resistant to penicillins, cephalosporins and monobactams". In this study imipenem was found as the most effective drug for treatment of ESBL positive as well as ESBL negative organisms followed by colistin, tigecycline, piperacillin/tazobactam. However, these drugs should be kept reserved and used only when other sensitive drugs are not available so that emergence of resistance against these drugs is deferred. While selecting antibiotic against ESBL positive organisms, it should be remembered that this group of organisms are relatively less sensitive than ESBL negative organisms. Also in cases of ESBL positive organisms, it seems prudent to avoid β-lactam antibiotics as far as possible.
